• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Banks
    Finance
    Savings Institutions
    Finance
    Get the next $BHLB alert in real time by email

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT).

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date 

    Index Name 

    Action 

    Company Name 

    Ticker 

    GICS Sector 

    September 2, 2025 

    S&P MidCap 400 

    Addition 

    Elanco Animal Health 

    ELAN 

    Health Care 

    September 2, 2025 

    S&P MidCap 400

    Deletion 

    Sarepta Therapeutics 

    SRPT 

    Health Care 

    September 2, 2025 

    S&P SmallCap 600 

    Addition 

    Sarepta Therapeutics 

    SRPT 

    Health Care 

    September 2, 2025 

    S&P SmallCap 600

    Deletion

    Brookline Bancorp

    BRKL

    Financials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected] 

    Media Inquiries

    [email protected] 

    Cision View original content:https://www.prnewswire.com/news-releases/elanco-animal-health-set-to-join-sp-midcap-400-sarepta-therapeutics-to-join-sp-smallcap-600-302539403.html

    SOURCE S&P Dow Jones Indices

    Get the next $BHLB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHLB
    $BRKL
    $ELAN
    $SPGI

    CompanyDatePrice TargetRatingAnalyst
    S&P Global Inc.
    $SPGI
    2/17/2026$575.00Buy
    BofA Securities
    Sarepta Therapeutics Inc.
    $SRPT
    1/28/2026$20.00Equal Weight
    Barclays
    Elanco Animal Health Incorporated
    $ELAN
    1/22/2026Neutral → Overweight
    Piper Sandler
    Sarepta Therapeutics Inc.
    $SRPT
    12/9/2025$32.00Outperform
    Wedbush
    Elanco Animal Health Incorporated
    $ELAN
    12/9/2025$30.00Overweight
    Barclays
    Elanco Animal Health Incorporated
    $ELAN
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    Elanco Animal Health Incorporated
    $ELAN
    11/19/2025$25.00Hold → Buy
    Argus
    Sarepta Therapeutics Inc.
    $SRPT
    11/5/2025$26.00Neutral → Outperform
    Mizuho
    More analyst ratings

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Joly Hubert bought $997,459 worth of shares (2,500 units at $398.98), increasing direct ownership by 1,515% to 2,665 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    2/12/26 4:01:28 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    President, S&P Global Mobility Eager William W bought $11,917 worth of shares (23 units at $517.58), increasing direct ownership by 0.26% to 8,724 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    1/15/26 4:01:18 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/10/26 4:15:53 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/10/26 4:15:26 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP and CFO Vanhimbergen Robert M

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/10/26 4:14:45 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    SEC Filings

    View All

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BofA Securities resumed coverage on S&P Global with a new price target

    BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $575.00

    2/17/26 7:30:15 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Barclays resumed coverage on Sarepta Therapeutics with a new price target

    Barclays resumed coverage of Sarepta Therapeutics with a rating of Equal Weight and set a new price target of $20.00

    1/28/26 7:19:11 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by Piper Sandler

    Piper Sandler upgraded Elanco Animal Health from Neutral to Overweight

    1/22/26 8:20:23 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Sarepta Therapeutics Inc.

    10-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

    3/2/26 7:02:15 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

    2/25/26 5:09:54 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

    2/25/26 4:10:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

    TORONTO, March 6, 2026 /CNW/ - As a result of the quarterly review, S&P Dow Jones Indices will make the following changes in the S&P/TSX Composite Index prior to the open of trading on Monday, March 23, 2026: S&P/TSX COMPOSITE INDEX – March 23, 2026COMPANYGICS SECTORGICS SUB-INDUSTRYADDEDAbraSilver Resource Corp. (TSX:ABRA)MaterialsDiversified Metals & MiningADDEDAvino Silver & Gold Mines Ltd. (TSX:ASM)MaterialsPrecious Metals & MineralsADDEDi-80 Gold Corp. (TSX:IAU)MaterialsGoldADDEDMontage Gold Corp. (TSX:MAU)MaterialsGoldADDEDAmericas Gold and Silver Corporation (TSX:USA)MaterialsDiversified Metals & MiningFor more information about S&P Dow Jones Indices, please visit www.spdji.comABOUT S

    3/6/26 5:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    US Secretary of the Interior Doug Burgum to Address CERAWeek by S&P Global in Houston, March 23-27

    World's preeminent energy conference to focus on 'Convergence and Competition: Energy, Technology and Geopolitics.' Learn more at www.ceraweek.comHOUSTON, March 5, 2026 /PRNewswire/ -- Chairman of the National Energy Dominance Council and Secretary of the Interior Doug Burgum will deliver a plenary address to delegates at the 44th annual CERAWeek by S&P Global, March 23-27 in Houston. He will join the world's energy industry leaders, experts, government officials and policymakers, as well as leaders from the technology, financial and industrial communities addressing this year's conference.

    3/5/26 2:27:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Financials

    Live finance-specific insights

    View All

    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

    Net product revenues for the full year 2025 totaled $1,864.3 million, consisting of $965.6 million of PMO net product revenue and $898.7 million of ELEVIDYS net product revenue Net product revenues for the fourth quarter 2025 totaled $369.6 million, consisting of $259.2 million of PMO net product revenue and $110.4 million of ELEVIDYS net product revenue Following refinancing of 2027 notes and corporate restructuring, overall financial position and capital structure strengthened to support full investment in our pipeline and marketed therapies Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for

    2/25/26 4:05:00 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

    Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre

    2/24/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 25, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2025 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After register

    2/11/26 8:30:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

    SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    11/13/24 10:27:59 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Brookline Bancorp Inc.

    SC 13G/A - BROOKLINE BANCORP INC (0001049782) (Subject)

    11/12/24 5:09:10 PM ET
    $BRKL
    Savings Institutions
    Finance

    Amendment: SEC Form SC 13G/A filed by Brookline Bancorp Inc.

    SC 13G/A - BROOKLINE BANCORP INC (0001049782) (Subject)

    11/12/24 10:03:30 AM ET
    $BRKL
    Savings Institutions
    Finance

    $BHLB
    $BRKL
    $ELAN
    $SPGI
    Leadership Updates

    Live Leadership Updates

    View All

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    S&P Global Appoints Chief Strategy Officer for Mobility Global Completing New Executive Leadership Team

    Martin Metzker to lead Strategy, Communications and Enterprise Marketing for Mobility Global in preparation for its planned separation into a standalone public companyNEW YORK, Feb. 19, 2026 /PRNewswire/ -- S&P Global (NYSE: SPGI) today announced the appointment of Martin Metzker as Chief Strategy Officer of S&P Global Mobility ("Mobility Global"), effective immediately. Mr. Metzker will be responsible for leading Mobility Global's Strategy function and overseeing Communications and Enterprise marketing for the business as it prepares for its planned separation from S&P Global into a standalone public company. Mr. Metzker joins the company from Boston Consulting Group, and will report to Bil

    2/19/26 4:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    RingCentral Set to Join S&P SmallCap 600

    NEW YORK, Feb. 9, 2026 /PRNewswire/ -- RingCentral Inc. (NYSE:RNG) will replace Hillenbrand Inc. (NYSE:HI) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, February 12. Lone Star Funds is acquiring Hillenbrand in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Feb 12, 2026 S&P SmallCap 600 Addition RingCentral RNG Information Technology Feb 12, 2026 S&P SmallCap 600 Deletion Hillenbrand HI Industrials ABOUT S&P DOW JONES INDICES S&P Dow Jones Indices is the large

    2/9/26 6:08:00 PM ET
    $HI
    $RNG
    $SPGI
    Miscellaneous manufacturing industries
    Consumer Discretionary
    EDP Services
    Technology